Mechanism of action

In preclinical models the reported activity of BPC-157 is described primarily through the nitric oxide system: the peptide modulates NO synthesis (eNOS) and, in rodent experiments, counteracts both NO blockade (L-NAME) and NO excess (L-arginine). Cell-based work reports activation of VEGFR2 with downstream Akt/eNOS signalling, which is linked to the angiogenesis and granulation-tissue formation observed in these models. Further described effects include increased cell migration via the FAK-paxillin pathway, altered expression of Egr-1 and its co-repressor NAB2 in relation to collagen and growth-factor genes, upregulation of the growth hormone receptor in tendon fibroblasts, dampening of pro-inflammatory NF-κB-dependent signalling, and stabilisation of the intestinal barrier. All of these statements come from animal and cell experiments; no mechanism has been confirmed in humans.

State of evidence

The evidence base for BPC-157 is almost entirely preclinical. Numerous rodent studies exist, among them Achilles tendon transection, muscle injury, colitis, NSAID-induced mucosal lesions and fistula models, complemented by in vitro work on fibroblasts and endothelial cells. A large share of these publications originates from the same research group around P. Sikiric in Zagreb and appeared in a narrow set of journals; independent replication is limited. The cited Seiwerth and Park publications are reviews, not independent controlled human studies. The cited evidence does not include a published controlled human trial. A 2025 uncontrolled intravenous pilot examined two participants who had already received BPC-157 before the study. It reported no short-term adverse effects or changes in selected laboratory biomarkers; its sample size, lack of control and brief observation establish neither reliable safety nor efficacy. Trial registries list a phase 1 study of PCO-02 from 2015 whose status has remained unknown since registration and for which no results are posted, plus a phase 2 trial in acute hamstring injury that started in 2026 and is currently recruiting, likewise without results. Those registry entries do not substitute for published controlled findings, and these scientific reports do not establish authorization of a particular research product. For pharmacokinetics, one published animal study exists (He et al., 2022): in rats and beagle dogs the elimination half-life after intravenous administration was below 30 minutes, with absolute intramuscular bioavailability of roughly 14 to 19 percent (rat) and 45 to 51 percent (dog). The multi-hour half-life figures circulating in secondary sources are not supported by these data; robust human data on kinetics, bioavailability and safety are lacking.

Questions about the research

What is BPC-157 investigated for in research?

Published work deals predominantly with tissue repair in animal models, for example healing of tendon, muscle, skin and bone, and with the integrity of the gastrointestinal mucosa after injury. In vitro studies on fibroblasts and endothelial cells add observations on cell migration and new vessel formation. These research questions describe the context of investigation and say nothing about efficacy in humans.

What is the state of the evidence on BPC-157?

The evidence remains predominantly preclinical, with limited independent replication. A 2025 uncontrolled intravenous pilot in two previously exposed participants reported no short-term adverse effects or selected laboratory changes, but does not reliably establish safety or efficacy. The cited registries include a phase 1 study of unknown status and a recruiting phase 2 trial without posted results. Registration of a trial is not a clinical finding or product authorization.

Sources

1. He et al., Front Pharmacol 2022 (PK in rat and dog)DOI: 10.3389/fphar.2022.1026182PMID: 36588717
2. Seiwerth et al., Curr Pharm Des 2018, review of BPC-157 researchDOI: 10.2174/1381612824666180712110447PMID: 29998800
3. Krivic et al., Inflamm Res 2008DOI: 10.1007/s00011-007-7056-8PMID: 18594781
4. Hsieh et al., J Mol Med 2017DOI: 10.1007/s00109-016-1488-yPMID: 27847966
5. Chang et al., J Appl Physiol 2011DOI: 10.1152/japplphysiol.00945.2010PMID: 21030672
6. Chang et al., Molecules 2014DOI: 10.3390/molecules191119066PMID: 25415472
7. Park et al., Curr Pharm Des 2020, review of BPC-157 researchDOI: 10.2174/1381612826666200523180301PMID: 32445447
8. ClinicalTrials.gov NCT02637284, PCO-02 phase 1 safety and pharmacokinetics, 2015 (status unknown)
9. ClinicalTrials.gov NCT07437547, phase 2 trial in acute hamstring strain, 2026 (recruiting)
10. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study, uncontrolled two-participant report, 2025PMID: 40131143

Mechanism of action

In preclinical models the reported activity of BPC-157 is described primarily through the nitric oxide system: the peptide modulates NO synthesis (eNOS) and, in rodent experiments, counteracts both NO blockade (L-NAME) and NO excess (L-arginine). Cell-based work reports activation of VEGFR2 with downstream Akt/eNOS signalling, which is linked to the angiogenesis and granulation-tissue formation observed in these models. Further described effects include increased cell migration via the FAK-paxillin pathway, altered expression of Egr-1 and its co-repressor NAB2 in relation to collagen and growth-factor genes, upregulation of the growth hormone receptor in tendon fibroblasts, dampening of pro-inflammatory NF-κB-dependent signalling, and stabilisation of the intestinal barrier. All of these statements come from animal and cell experiments; no mechanism has been confirmed in humans.

State of evidence

The evidence base for BPC-157 is almost entirely preclinical. Numerous rodent studies exist, among them Achilles tendon transection, muscle injury, colitis, NSAID-induced mucosal lesions and fistula models, complemented by in vitro work on fibroblasts and endothelial cells. A large share of these publications originates from the same research group around P. Sikiric in Zagreb and appeared in a narrow set of journals; independent replication is limited. The cited Seiwerth and Park publications are reviews, not independent controlled human studies. The cited evidence does not include a published controlled human trial. A 2025 uncontrolled intravenous pilot examined two participants who had already received BPC-157 before the study. It reported no short-term adverse effects or changes in selected laboratory biomarkers; its sample size, lack of control and brief observation establish neither reliable safety nor efficacy. Trial registries list a phase 1 study of PCO-02 from 2015 whose status has remained unknown since registration and for which no results are posted, plus a phase 2 trial in acute hamstring injury that started in 2026 and is currently recruiting, likewise without results. Those registry entries do not substitute for published controlled findings, and these scientific reports do not establish authorization of a particular research product. For pharmacokinetics, one published animal study exists (He et al., 2022): in rats and beagle dogs the elimination half-life after intravenous administration was below 30 minutes, with absolute intramuscular bioavailability of roughly 14 to 19 percent (rat) and 45 to 51 percent (dog). The multi-hour half-life figures circulating in secondary sources are not supported by these data; robust human data on kinetics, bioavailability and safety are lacking.

Questions about the research

What is BPC-157 investigated for in research?

Published work deals predominantly with tissue repair in animal models, for example healing of tendon, muscle, skin and bone, and with the integrity of the gastrointestinal mucosa after injury. In vitro studies on fibroblasts and endothelial cells add observations on cell migration and new vessel formation. These research questions describe the context of investigation and say nothing about efficacy in humans.

What is the state of the evidence on BPC-157?

The evidence remains predominantly preclinical, with limited independent replication. A 2025 uncontrolled intravenous pilot in two previously exposed participants reported no short-term adverse effects or selected laboratory changes, but does not reliably establish safety or efficacy. The cited registries include a phase 1 study of unknown status and a recruiting phase 2 trial without posted results. Registration of a trial is not a clinical finding or product authorization.

Sources

1. He et al., Front Pharmacol 2022 (PK in rat and dog)DOI: 10.3389/fphar.2022.1026182PMID: 36588717
2. Seiwerth et al., Curr Pharm Des 2018, review of BPC-157 researchDOI: 10.2174/1381612824666180712110447PMID: 29998800
3. Krivic et al., Inflamm Res 2008DOI: 10.1007/s00011-007-7056-8PMID: 18594781
4. Hsieh et al., J Mol Med 2017DOI: 10.1007/s00109-016-1488-yPMID: 27847966
5. Chang et al., J Appl Physiol 2011DOI: 10.1152/japplphysiol.00945.2010PMID: 21030672
6. Chang et al., Molecules 2014DOI: 10.3390/molecules191119066PMID: 25415472
7. Park et al., Curr Pharm Des 2020, review of BPC-157 researchDOI: 10.2174/1381612826666200523180301PMID: 32445447
8. ClinicalTrials.gov NCT02637284, PCO-02 phase 1 safety and pharmacokinetics, 2015 (status unknown)
9. ClinicalTrials.gov NCT07437547, phase 2 trial in acute hamstring strain, 2026 (recruiting)
10. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study, uncontrolled two-participant report, 2025PMID: 40131143